<DOC>
	<DOCNO>NCT01379170</DOCNO>
	<brief_summary>Background study : Thyroid hormone , thyroxine ( T4 ) triiodothyronine ( T3 ) , know promote weight loss , could beneficial treat obesity , type 2 diabetes . Thyroid hormone treatment stimulate energy expenditure result increase body heat production , brown adipose tissue play important role . It hypothesize thyroid hormone would induce increased energy expenditure via process call mitochondrial uncoupling , thereby create inefficient energy status . Indeed , vivo study show 70 % increase flux tricarboxylic acid cycle ( TCA ) unchanged ATP synthesis rate upon T3 treatment lean , healthy young men . The disproportionate increase TCA flux compare ATP synthesis suggest increase mitochondrial uncoupling . It however unknown whether increase mitochondrial uncoupling would increase fat oxidation exerts favorable effect insulin sensitivity . There compel evidence type 2 diabetic patient high level fat accumulation non-adipose tissue , skeletal muscle , heart liver . Ectopic fat accumulation relate insulin resistance , however , fat accumulates peripheral organ know . Recently , study report compromised mitochondrial oxidative capacity type 2 diabetic patient first-degree relative diabetic patient , suggest play important role . Therefore , subject suffer overweight and/or type 2 diabetes overt hypothyroidism form interest group examine metabolic effect thyroid hormone treatment , less known effect thyroid hormone treatment group . Objective study : The purpose study evaluate whether thyroid hormone replacement therapy type 2 diabetic patient suffer overt hypothyroidism , improve muscular mitochondrial function , low ectopic fat accumulation muscle liver , increase brown adipose tissue activity enhance insulin sensitivity . Study design : Type 2 diabetic patient diagnose hypothyroidism undergo 3 month thyroid hormone replacement therapy ( THRT ) ( Euthyrox® , Merck , Germany ) . Patients metabolically characterize ( insulin sensitivity fat accumulation peripheral tissue ) thyroid hormone replacement therapy . Study population : 17 type 2 diabetic patient diagnose overt hypothyroidism ( 9 Netherlands , 8 Germany PET-CT ) Primary study parameters/outcome study : Thyroid hormone-induced change whole body insulin sensitivity ( change insulin-stimulated glucose disposal ) muscle mitochondrial function . Secondary study parameters/outcome study ( applicable ) : Thyroid hormone-induced change lipid content skeletal muscle liver brown adipose tissue activity .</brief_summary>
	<brief_title>Thyroid Study Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypothyroidism</mesh_term>
	<criteria>Male postmenopausal female Age 4065 year Body mass index ( BMI ) &lt; 40 &gt; 27 kg/m2 Stable dietary habit ( weight loss/gain &gt; 3 kg last 6 month ) Stable physical activity level least six month Newly diagnose hypothyroid , noninsulin dependent type 2 diabetic patient TSH value higher &gt; 4.0 mU/l lower concentration free T4 &lt; 8.0 pmol/l . Type 2 diabetic patient use sulphonylurea metformin therapy least six month constant dose least two month . Hypothyroid diabetic patient due Hashimoto disease ( TPO &gt; 100 IE/ml ; Tg &gt; 344 IE/ml ) , autoantibodies glutamic acid decarboxylase ( GAD ) , IA2 insulin exclude type 2 polyglandular autoimmune syndrome ( PGAII ) ( exclude type 1 diabetes ) . Type 2 diabetic patient HbA1c level &lt; 8.0 % Type 2 diabetic patient include diabetesrelated comorbidities like cardiovascular disease , diabetic foot , polyneuropathy , retinopathy . Unstable body weight Participation intensive weightloss program vigorous exercise program last year start study Medical history include active cardiovascular disease , i.e . history coronary artery disease ( i.e . history angina pectoris , percutaneous transluminal coronary angioplasty coronary artery bypass graft ) cardiac arrhythmia . Liver disease liver dysfunction ( ALT &gt; 2.5 x increase ) Impaired renal function ( creatinine &gt; 120 umol/L ) Systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg Hb &lt; 7.4 mmol/l ( 12 g/dl ) woman , &lt; 8.1 mmol/l ( 13 g/dl ) men Abuse drug and/or alcohol Contraindications MRI scanning ( please see appendix III : MRI contraindication questionnaire ) Patients history thyroid cancer Patients use α and/or β blocker Severe diabetes require application insulin patient diabetesrelated complication History psychiatric disease Diabetes related comorbidities like cardiovascular disease , diabetic foot , polyneuropathy , retinopathy . Use medication know interfere glucose homeostasis ( i.e . corticosteroid , thiazolidinediones ) Hypothyroid diabetic patient due Hashimoto disease positive test value autoantibody GAD , IA2 insulin exclude type 1 diabetes . Use anticoagulant , platelet aggregation inhibitor . Patients donate blood past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>brown adipose tissue</keyword>
	<keyword>mitochondrial dysfunction</keyword>
	<keyword>insulin resistance</keyword>
</DOC>